Listen: JPM21: Déjà vu in Alzheimer’s research, debatable valuations in biotech, and OWS’s legacy
Is Alzheimer’s research stuck in a rut? Can genome editing live up to the hype?…
Category: JPM2021
Virtual Event: STAT@JPM: Facing 2021
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET….
STAT+: With durable monkey data, Verve selects its first CRISPR base editing treatment for human trials
Verve Therapeutics said Tuesday its one-time treatment that uses the “base editing” form of CRISPR…
STAT+: Gilead’s remdesivir sales are surging, but investors aren’t impressed
A lot more Covid-19 patients in the U.S. are being treated with Gilead Sciences’ remdesivir…
STAT+: Lilly’s preliminary Alzheimer’s data adds $4 billion to Biogen’s value
Biogen added more than $4 billion in market value on Monday after a rival Alzheimer’s…
STAT+: Vertex Pharma taking more aggressive M&A stance, flush with cash from cystic fibrosis drugs
Vertex Pharmaceuticals is looking to acquire “mid- and late-stage assets” to bolster its current research…
STAT+: Bluebird Bio intends to split into two companies, but for now, its troubles are also divided
Splitting Bluebird Bio into two publicly traded companies — one focused on cell therapies for…
STAT+: Tempus unveils prototype cube that talks back to oncologists
Tempus, a Chicago-based health technology company, wants oncologists to talk to the cube. The cube,…
STAT+: Company dedicated to cutting drug prices raises lots of money, releases few details
EQRx, a startup that made waves last year when it announced a plan to develop…
STAT+: Eli Lilly says drug slowed Alzheimer’s decline in preliminary study
An experimental medicine appeared to slow the decline of patients with the early symptoms of…